A Structure-Activity Study of the Inhibition of HIV-1 Tat-Dependent Trans-Activation by Mixmer 2′-O-Methyl Oligoribonucleotides Containing Locked Nucleic Acid (LNA), α-L-LNA, or 2′-Thio-LNA Residues

Oligonucleotides

Volumn 13, Issue 6, 2003, Pages 435-453

  Arzumanov, Andrey ^a   Stetsenko, Dmitry A ^a   Malakhov, Andrey D ^a   Reichelt, Stefanie ^a   Sørensen, Mads D ^b   Babu, B Ravindra ^b   Wengel, Jesper ^b   Gait, Michael J ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2' O METHYL OLIGORIBONUCLEOTIDE; 2' THIO LOCKED NUCLEIC ACID; ALPHA LEVO LOCKED NUCLEIC ACID; CATIONIC GEMINI SURFACTANT; CATIONIC SURFACTANT; FIBROBLAST GROWTH FACTOR; GS11 PROTEIN; KAPOSI FIBROBLAST GROWTH FACTOR; LOCKED NUCLEIC ACID; LUCIFERASE; NUCLEIC ACID; OLIGONUCLEOTIDE; OLIGORIBONUCLEOTIDE; PROTEIN; RENILLA LUCIFERIN 2 MONOOXYGENASE; TRANSACTIVATOR PROTEIN; TRANSCRIPTION ELONGATION FACTOR; TRANSPORTAN PEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; CELL ACTIVITY; CELL NUCLEUS; CELL TRANSPORT; CHIMERA; CONJUGATION; CONTROLLED STUDY; COVALENT BOND; DISSOCIATION CONSTANT; DNA RESPONSIVE ELEMENT; DNA TEMPLATE; GENE EXPRESSION REGULATION; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; LONG TERMINAL REPEAT; MIXMER; PLASMID; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN RNA BINDING; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION; TRANSACTIVATION; TRANSACTIVATION RESPONSIVE ELEMENT; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

CALCITRIOL; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTORS; FLOW CYTOMETRY; GALANIN; GENE PRODUCTS, TAT; GENES, REPORTER; HELA CELLS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; LUCIFERASES; MICROSCOPY, FLUORESCENCE; MOLECULAR STRUCTURE; NUCLEAR PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; OLIGORIBONUCLEOTIDES; PROTO-ONCOGENE PROTEINS; RECOMBINANT FUSION PROTEINS; RNA-BINDING PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; THIONUCLEOTIDES; TRANS-ACTIVATION (GENETICS); WASP VENOMS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RENILLA; RNA VIRUSES;

EID: 1542333748     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/154545703322860762     Document Type: Article

References (55)

1. ARZUMANOV, A., and GAIT, M.J. (1999). Inhibition of the HIV-1 Tat protein-TAR RNA interaction by 2′-O-methyl oligoribonucleotides. Collection Symp. Ser. 2, 168-174.
2. ARZUMANOV, A., WALSH, A.P., LIU, X., RAJWANSHI, V.K., WENGEL, J., and GAIT, M.J. (2000). XIV International Round Table. Nucleosides, Nucleotides and Their Biological Applications. (International Medical Press, San Francisco), p. 24.
3. ARZUMANOV, A., WALSH, A.P., LIU, X., RAJWANSHI, V.K., WENGEL, J., and GAIT, M.J. (2001a). Oligonucleotide analogue interference with the HIV-1 Tat protein-TAR RNA interaction. Nucleos. Nucl. Nucleot. and Nucleic Acids 20, 471-480.
4. ARZUMANOV, A., WALSH, A.P., RAJWANSHI, V.K., KUMAR, R., WENGEL, J., and GAIT, M.J. (2001b). Inhibition of HIV-1 Tat-dependent trans-activation by steric block chimeric 2′-O-methyl/LNA oligoribonucleotides. Biochemistry 40, 14645-14654.
5. ASTRIAB-FISHER, A., SERGUEEV, D., FISHER, M., RAMSAY SHAW, B., and JULIANO, R.L. (2002). Conjugates of antisense oligonucleotides with the Tat and Antennapedia cell-penetrating peptides: Effect on cellular uptake, binding to target sequences, and biologic actions. Pharmaceut. Res. 19, 744-754.
6. BAKER, B.F., LOT, S.S., CONDON, T.P., CHENG-FLOURNEY, S., LESNIK, E.A., SASMOR, H.M., and BENNETT, C.F. (1997). 2′-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule I (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem. 272, 11994-12000.
7. BRAASCH, D.A., LIU, Y., and COREY, D.R. (2002). Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: Effect of mRNA target sequence and chimera design. Nucleic Acids Res. 30, 5160-5167.
8. BRAMLAGE, B., LUZI, E., and ECKSTEIN, F. (1998). Designing ribozymes for the inhibition of gene expression, TIBTECH 16, 434-438.
9. CHILDS, J.L., DISNEY, M.D., and TURNER, D.H. (2002). Oligonucleotide directed misfolding of RNA inhibits Candida albicans group I intron splicing. Proc. Natl. Acad. Sci. USA 99, 11091-11096.
10. DARFEUILLE, F., ARZUMANOV, A., GAIT, M.J., DI PRIMO, C., and TOULMÉ, J.J. (2002a). 2′-O-Methyl RNA hairpins generate loop-loop complexes and selectively inhibit HIV-1 Tat-mediated transcription. Biochemistry 41, 12186-12192.
11. DARFEUILLE, F., ARZUMANOV, A., GRYAZNOV, S., GAIT, M.J., DI PRIMO, C., and TOULMÉ, J.J. (2002b). Loop-loop interaction of HIV-1 TAR RNA with N3′ -5′ deoxyphosphoramidate aptamers inhibits in vitro Tat-mediated transcription. Proc. Natl. Acad. Sci. USA 99, 9709-9714.
12. DEAN, N.M. (2001). Functional genomics and target validation approaches using antisense oligonucleotide technology. Curr. Opin. Biotechnol. 12, 622-625.
13. DIAS, N., DHEUR, S., NIELSEN, P.E., GRYAZNOV, S., VAN AERSCHOT, A., HERDEWIJN, P., HÉLÈNE, C., and SAISON-BEHMOARAS, T.E. (1999). Antisense PNA tridecamers targeted to the coding region of Ha-ras mRNA arrest polypeptide chain elongation. J. Mol. Biol. 294, 403-416.
14. DINGWALL, C., ERNBERG, I., GAIT, M.J., GREEN, S.M., HEAPHY, S., KARN, J., LOWE, A.D., SINGH, M., and SKINNER, M.A. (1990). HIV-1 tat protein stimulates transcription by binding to a U-rich bulge in the stem of the TAR RNA structure. EMBO J. 9, 4145-4153.
15. DOKKA, S., TOLEDO-VELASQUEZ, D., SHI, X., WANG, L., and ROJANASUKUL, Y. (1997). Cellular delivery of oligonucleotides by synthetic import peptide carrier. Pharmaceut. Res. 14, 1759-1764.
16. DOYLE, D.F., BRAASCH, D.A., SIMMONS, C.G., JANOWSKI, B.A., and COREY, D.R. (2001). Inhibition of gene expression inside cells by peptide nucleic acids: Effect of mRNA target sequence, mismatched bases, and PNA length. Biochemistry 40, 53-64.
17. ELAYADI, A.N., BRAASCH, D.A., and COREY, D.R. (2002). Implications of high-affinity hybridization by locked nucleic acid oligomers for inhibition of human telomerase. Biochemistry 41, 9973-9981.
18. FARIA, M., SPILLER, D.G., DUBERTRET, C., NELSON, J.S., WHITE, M.R.H., SCHERMAN, D., HÉLÈNE, C., and GIOVANNANGELI, C. (2001). Phosphoramidate oligonucleotides as potent antisense molecules in cells in vivo. Nat. Biotech. 19, 40-44.
19. GILES, R.V., SPILLER, D.G., CLARK, R.E., and TIDD, D.M. (1999). Antisense morpholino oligonucleotide analog induces missplicing of c-myc mRNA. Antisense Nucleic Acid Drug Dev. 9, 213-220.
20. HAMMA, T., SALEH, A., HUQ, I., RANA, T.M., and MILLER, P.S. (2003). Inhibition of HIV Tat-TAR interactions by an antisense oligo-2′ -O-methylribonucleoside methylphosphonate. Bioorg. Med. Chem. Lett. 13, 1845-1848.
21. HOLMES, S.C., ARZUMANOV, A., and GAIT, M.J. (2003). Steric inhibition of human immunodeficiency virus type-1 Tat-dependent trans-activation in vitro and in cells by oligonucleotides containing 2′-O-methyl G-clamp ribonucleoside analogues. Nucleic Acids Res. 31, 2759-2768.
22. HWANG, S., TAMILARISU, N., KIBLER, K., CAO, H., ALI, A., PING, Y.-H., JEANG, K.-T., and RANA, T.M. (2003). Discovery of a small molecule Tat-trans-activation-responsive RNA antagonist that potentially inhibits human immunodeficiency virus-1 replication. J. Biol. Chem. 278, 39092-39103.
23. IYER, R.P., KUCHIMANCHI, S.N., and PANDEY, R.K. (2003). RNA interference: An exciting new approach for target validation, gene expression analysis and therapeutics. Drugs Future 28, 51-59.
24. KARN, J. (1999). Tackling Tat. J. Mol. Biol. 293, 235-254.
25. KARRAS, J.G., MAIER, M.A., WATT, A., and MANOHARAN, M. (2001). Peptide nucleic acids are potent modulators of endogenous pre-mRNA splicing of the murine interleukin-5 receptor a chain. Biochemistry 40, 7853-7859.
26. KAUSHIK, N., BASU, A., PALUMBO, P., NYERS, R.L., and PANDEY, V.N. (2002a). Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production. J. Virol. 76, 3881-3891.
27. KAUSHIK, M.J., BASU, A., and PANDEY, P.K. (2002b). Inhibition of HIV-1 replication by anti-transactivation responsive polyamide nucleotide analog. Antiviral Res. 56, 13-27.
28. KOSHKIN, A.A., SINGH, S.K., NIELSEN, P., RAJWANSHI, V.K., KUMAR, R., MELDGAARD, M., OLSEN, C.E., and WENGEL, J. (1998). LNA (locked nucleic acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron 54, 3607-3630.
29. KUMAR, R., SINGH, S.K., KOSHKIN, A.A., RAJWANSHI, V.K., MELDGAARD, M., and WENGEL, J. (1998). The first analogues of LNA (locked nucleic acids): Phosphorothioate-LNA and 2′-thio-LNA. Bioorg. Med. Chem. Lett. 8, 2219-2222.
30. MANN, C.J., HONEYMAN, K., CHENG, A.J., LY, T., LLOYD, F., FLETCHER, S., MORGAN, J.E., PARTRIDGE, T.A., and WILTON, S.D. (2001). Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc. Natl. Acad. Sci. USA 98, 42-47.
31. MARCUSSON, E.G., BHAT, B., MANOHARAN, M., BENNETT, C.F., and DEAN, N.M. (1998). Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus. Nucleic Acids Res. 26, 2016-2023.
32. MAYHOOD, T., KAUSHIK, N., PANDEY, P.K., KASHANCHI, F., DENG, L., and PANDEY, V.N. (2000). Inhibition of Tat-mediated transactivation of HIV-1 LTR transcription by polyamide nucleic acid targeted to the TAR hairpin element. Biochemistry 39, 11532-11539.
33. McGREGOR, C., PERRIN, C., MONCK, M., CAMILLERI, P., and KIRBY, A.J. (2001). Rational approaches to the design of cationic gemini surfactants for gene delivery. J. Am. Chem. Soc. 26, 6215-6220.
34. McKNIGHT, K.L., and HEINZ, B.A. (2003). RNA as a target for developing antivirals. Antiviral Chem. Chemother. 14, 61-73.
35. MERCATANTE, D.R., and KOLE, R. (2002). Control of alternative splicing by antisense oligonucleotides as a potential chemotherapy: Effects on gene expression. Biochim. Biophys. Acta 1587, 126-132.
36. MESTRE, B., ARZUMANOV, A., SINGH, M., BOULMÉ, F., LITVAK, S., and GAIT, M.J. (1999). Oligonucleotide inhibition of the interaction of HIV-1 Tat protein with the transactivation responsive region (TAR) of HIV RNA. Biochim. Biophys. Acta 1445, 86-98.
37. MONIA, B.P., LESNIK, E.A., GONZALEZ, C., LIMA, W.F., McGEE, D., GUINOSSO, C.J., KAWASAKI, A.M., COOK, P.D., and FREIER, S.M. (1993). Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268, 14514-14522.
38. OPALINSKA, J.B., and GEWIRTZ, A.M. (2002). Nucleic-acid therapeutics: Basic principles and recent applications. Nat. Rev. 1, 503-514.
39. PETERSEN, M., HAKANSSON, A.E., WENGEL, J., and JACOBSEN, J.P. (2001). α-L-LNA (α-L-ribo configured locked nucleic acid) recognition of RNA. A study by NMR spectroscopy and molecular dynamics simulations. J. Am. Chem. Soc. 123, 7431-7432.
40. RAJWANSHI, V.K., HÅKANSSON, A.E., DAHL, B.M., and WENGEL, J. (1999). LNA stereoisomers: Xylo-LNA (β-D-xylo configures locked nucleic acid) and α-L-LNA (α-L-ribo configured locked nucleic acid). Chem. Commun. 1395-1396.
41. RANA, T.M., and JEANG, K.-T. (1999). Biochemical and functional interactions between HIV-1 Tat protein and TAR RNA. Arch. Biochem. Biophys. 365, 175-185.
42. RICHTER, S., CAO, H., and RANA, T.M. (2002). Specific HIV-1 TAR RNA loop sequence and functional groups are required for human cyclin T1-Tat-TAR terniary complex formation. Biochemistry 41, 6391-6397.
43. SAZANI, P., KANG, S.-H., MAIER, M.A., WEI, C., DILLMAN, J., SUMMERTON, J., MANOHARAN, M., and KOLE, R. (2001). Nuclear antisense effects of neutral, anionic and cationic analogs. Nucleic Acids Res. 29, 3965-3974.
44. SCHMAJUK, G., SIERAKOWSKA, H., and KOLE, R. (1999). Antisense oligonucleotides with different backbones. Modification of splicing pathways and efficacy of uptake. J. Biol. Chem. 274, 21783-21789.
45. SCHMITZ, J.C., YU, D., AGRAWAL, S., and CHU, E. (2001). Effect of 2′-O-methyl antisense ORNs on expression of thymidylate synthase in human colon cancer RKO cells. Nucleic Acids Res. 29, 415-422.
46. SOOMETS, U., KILK, T., and LANGEL, U. (2001). In: Innovations and Perspectives in Solid Phase Synthesis & Combinatorial Libraries 2000. R. Epton, ed. (Mayflower Press, Kingswinford, U.K.), pp. 131-136.
47. SØRENSEN, M.D., KVÍRNØ, L., BRYLD, T., HAKANSSON, A.E., VERBEURE, B., GAUBERT, G., HERDEWIJN, P., and WENGEL, J. (2002). α-L-Ribo-configured locked nucleic acid (α-L-LNA): Synthesis and properties. J. Am. Chem. Soc. 124, 2164-2176.
48. STETSENKO, D.A., and GAIT, M.J. (2001). A convenient solid-phase method for synthesis of 3′-conjugates of oligonucleotides. Bioconj. Chem. 12, 576-586.
49. STETSENKO, D.A., MALAKHOV, A.D., and GAIT, M.J. (2002). Total stepwise solid-phase synthesis of oligonucleotide (3′-N)-peptide conjugates. Organic Lett. 4, 3259-3262.
50. TAUBE, R., FUJINAGA, K., WIMMER, J., BARBORIC, M., and PETERLIN, B.M. (1999). Tat transactivation: A model for the regulation of eukaryotic transcriptional elongation. Virology 264, 245-253.
51. TOULMÉ, J.J. (2001). New candidates for true antisense. Nat. Biotech. 19, 17-18.
52. VICKERS, T.A., BAKER, B.F., COOK, P.D., ZOUNES, M., BUCKHEIT, R.W., GERMANY, J., and ECKER, D.J. (1991). Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element. Nucleic Acids Res. 19, 3359-3368.
53. VICKERS, T.A., WYATT, J.R., BURCKIN, T., BENNETT, C.F., and FREIER, S.M. (2001). Fully modified 2′-MOE oligonucleotides redirect polyadenylation. Nucleic Acids Res. 29, 1293-1299.
54. WAHLESTEDT, C., SALMI, P., GOOD, L., KELA, J., JOHNSSON, T., HÖKFELT, T., BROBERGER, C., PORRECA, F., LAI, J., REN, K., et al. (2000). Potent and non-toxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl. Acad. Sci. USA 97, 5633-5638.
55. WILSON, W.D., and LI, K. (2000). Targeting RNA with small molecules. Curr. Med. Chem. 7, 73-98.